Aradigm is an emerging specialty pharmaceutical company engaged in developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases. The company’s product candidates address the treatment of bronchiectasis, cystic fibrosis, inhalation tularemia, anthrax infections and smoking cessation. The company is actively focused on fulfilling its promise to develop inhalation drug products that can potentially revolutionize the quality of life for patients with severe pulmonary disease. For more information, visit the company’s Web site at www.aradigm.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: